Current Hepatology Reports

, Volume 13, Issue 1, pp 35–42

Current Management Strategies for Acute Esophageal Variceal Hemorrhage

Authors

  • Brett Fortune
    • Section of Digestive DiseasesYale University School of Medicine
    • Section of Digestive DiseasesYale University School of Medicine
    • Section of Digestive Diseases, VA-CT Healthcare System
Management of the Cirrhotic Patient (NS Reau and A Cardenas, Section editors)

DOI: 10.1007/s11901-014-0221-y

Cite this article as:
Fortune, B. & Garcia-Tsao, G. Curr Hepatology Rep (2014) 13: 35. doi:10.1007/s11901-014-0221-y

Abstract

Acute esophageal variceal hemorrhage is one of the clinical events that define decompensated cirrhosis and is associated with high rates of morbidity and mortality. Although recent treatment strategies have led to improved outcomes, variceal hemorrhage still carries a 6-week mortality rate of 15-20 %. Current standards in its treatment include antibiotic prophylaxis, infusion of a vasoactive drug and endoscopic variceal ligation. The placement of a transjugular intrahepatic portosystemic shunt (TIPS) is considered for patients that have treatment failure or recurrent bleeding. Recurrent hemorrhage is prevented with the combination of a non-selective beta-blocker and endoscopic variceal ligation. These recommendations however assume that all patients with cirrhosis are equal. Based on a review of recent evidence, a strategy in which patients are stratified by Child class, the main predictor of outcomes, is proposed.

Keywords

CirrhosisPortal hypertensionVariceal hemorrhageRisk stratificationHemorrhage controlProphylactic antibioticsOctreotideEsophageal variceal ligationEsophageal stentTransjugular intrahepatic portosystemic stentRecurrent hemorrhageSecondary prophylaxisNonselective beta-blockersCarvedilol

Copyright information

© Springer Science+Business Media New York (outside the USA) 2014